Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AU2 in Relapsed and Previously Untreated CLL Patients
NCT04624633Phase 2Active, not recruiting
- Start
- Dec 2020
- Primary completion
- Dec 2023
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of acalabrutinib tablet (Variant 1), umbralisib, ublituximab in chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL). Started Dec 2020; status: active, not recruiting.
02
Drugs
acalabrutinib tablet (Variant 1)umbralisibublituximab
03
Conditions
chronic lymphocytic leukemia (CLL)small lymphocytic lymphoma (SLL)
Beyond the preview
Go deeper on NCT04624633.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04624633.